Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia

被引:0
|
作者
M Das
T K Saikia
S H Advani
P M Parikh
S Tawde
机构
[1] Bone Marrow Transplant Unit,Department of Medical Oncology
[2] Tata Memorial Hospital,undefined
来源
关键词
reduced intensity conditioning regimen; graft-versus-host disease; immunosuppression;
D O I
暂无
中图分类号
学科分类号
摘要
Reduced-intensity conditioning that harnesses the potential of a graft-versus-tumor (GVT) effect has been proposed as an alternative to conventional myeloablative allogeneic stem cell transplantation. The primary aim is engraftment and this can be achieved with minimal immunosuppression. In this report, we describe the use of such regimens for CML in 17 patients who received human leukocyte antigen (HLA)-matched sibling allografts. Conditioning was with fludarabine, antithymocyte globulin (ATG) and busulfan for the first 11 patients, whereas fludarabine, busulfan and TBI were used for the remaining six patients. Engraftment was prompt in most of the cases. Complications and need for supportive therapy in the immediate post-transplant period were reduced drastically. Only two patients (both in the TBI group) died within the first 100 days. Acute graft-versus-host disease (GVHD) grade II–IV was seen in seven patients. Complications occurred later on. Chronic GVHD was observed in 11/17 patients. Lung infection and GVHD were the major killers. In surviving patients, after a median follow-up of 30 months (range 37–21 months), 6/17 (35.3%) are alive. Five are disease free and one patient is still in relapse even after a second donor lymphocyte infusion. Total treatment time and cost were more than with conventional transplants. We conclude that reduced-intensity transplantation still requires further refinement.
引用
收藏
页码:125 / 129
页数:4
相关论文
共 50 条
  • [31] Reduced-intensity conditioning allogeneic hematopoietic cell transplantation using oral fludarabine as part of the conditioning regimen
    Delgado, J.
    Marco, A.
    Moreno, E.
    Pinana, J. L.
    Valcarcel, D.
    Martino, R.
    Briones, J.
    Sureda, A.
    Brunet, S.
    Sierra, J.
    CYTOTHERAPY, 2009, 11 (03) : 356 - 361
  • [32] A PROSPECTIVE RANDOMIZED STUDY COMPARING REDUCED-INTENSITY CONDITIONING AND MYELOABLATIVE CONDITIONING IN PATIENTS WITH MYELOID LEUKEMIA UNDERGOING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
    Ringden, O.
    Erkers, T.
    Aschan, J.
    Le Blanc, K.
    Hagglund, H.
    Omazic, B.
    Svenberg, P.
    Ljungman, P.
    Mattsson, J.
    Remberger, M.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2012, 18 (02) : S335 - S335
  • [33] Allogeneic hematopoietic stem cell transplantation for relapsed acute myeloid leukemia in ETO positive with reduced-intensity conditioning
    Guo, Zhi
    Xu, Chen
    Chen, Hu
    ONCOTARGET, 2018, 9 (01) : 524 - 538
  • [34] Allogeneic hematopoietic stem cell transplantation using reduced intensity conditioning regimen for patients with acute myeloid leukemia not in complete remission
    Shimomura, Yoshimitsu
    Kitamura, Tetsuhisa
    Yanada, Masamitsu
    Mizuno, Shohei
    Kondo, Tadakazu
    Yoshihara, Satoshi
    Tanaka, Masatsugu
    Inai, Kazuki
    Katayama, Yuta
    Onizuka, Makoto
    Fukuda, Takahiro
    Nakamae, Hirohisa
    Kurokawa, Mineo
    Yano, Shingo
    Nara, Miho
    Masuko, Masayoshi
    Miyakoshi, Shigesaburo
    Eto, Tetsuya
    Yoshimitsu, Makoto
    Ishimaru, Fumihiko
    Kanda, Junya
    Atsuta, Yoshiko
    Konuma, Takaaki
    CYTOTHERAPY, 2025, 27 (03) : 316 - 323
  • [35] What is the optimal reduced-intensity conditioning regimen for patients with classical Hodgkin lymphoma undergoing allogeneic transplantation? - is there a one to use or avoid
    Epperla, Narendranath
    BRITISH JOURNAL OF HAEMATOLOGY, 2020, 190 (04) : 490 - 492
  • [36] Immunomodulation in patients with solid tumour progressing after allogeneic stem cell transplantation and reduced-intensity conditioning regimen
    Sarina, B
    Mazza, R
    Castagna, L
    Todisco, E
    Bertani, G
    Timofeeva, I
    BONE MARROW TRANSPLANTATION, 2005, 35 : S203 - S203
  • [37] Nephrotic syndrome after allogeneic transplantation of haematopoietic stem cell with a reduced-intensity conditioning regimen
    Benakli, M.
    Ahmed-Nacer, R.
    Talbi, A.
    Mehdid, F.
    Belhadj, R.
    Rahmoune, N.
    Hamladji, R. M.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S279 - S279
  • [38] Reduced-intensity conditioning with thiotepa, fludarabine and melphalan is an effective regimen for allogeneic transplantation in multiple myeloma
    Majolino, I
    Arana, MG
    Riccardi, M
    Locasciulli, A
    Bacigalupo, A
    Di Bartolomeo, P
    Scimè, R
    Olivieri, A
    Narni, F
    Bregni, M
    De Fabritiis, P
    Musso, M
    Corradini, P
    BONE MARROW TRANSPLANTATION, 2005, 35 : S70 - S70
  • [39] Reduced-intensity conditioning regimen for allogeneic stem cell transplantation in an adult patient with Down's syndrome and acute myeloid leukaemia
    Tendas, A.
    Dentamaro, T.
    Cupelli, L.
    Niscola, P.
    Scaramucci, L.
    Giovannini, M.
    Ales, M.
    Spagnoli, A.
    Bruno, A.
    Coletta, A. M.
    Giovagnorio, R.
    Perrotti, A. P.
    De Fabritiis, P.
    BONE MARROW TRANSPLANTATION, 2009, 43 : S374 - S375
  • [40] Gemtuzumab ozogamicin (Mylotarg®) as part of reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in patients with relapsed acute myeloid leukemia.
    Bornhaeuser, M
    Illmer, T
    Platzbecker, U
    Schetelig, J
    Schaich, M
    Kiani, A
    Schuler, U
    Ehninger, G
    BLOOD, 2004, 104 (11) : 351A - 352A